A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999.
It is a $247B healthcare company. Revenue grew 8.6% over the last year, it keeps 17¢ of every dollar of sales as profit, and its net debt equals ~2.6 years of free cash flow. It trades at 23.4× earnings — around the middle of its own history.
- Website
- astrazeneca.com
- Employees
- 96 100
- Sector
- Healthcare
- Founded
- 1913
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong growth and quality.
Valuation72
- P/E vs own history35th pct · 20/25
- FCF yield4.3% · 12/25
- P/S4.0x · 20/25
- EV/EBITDA14.9x · 20/25
Growth95
- Revenue CAGR11.9% · 20/25
- Net income CAGR209.1% · 25/25
- EPS CAGR ~5Y209.0% · 25/25
- Fwd implied growth54.3% · 25/25
Profitability72
- ROIC13.2% · 12/25
- ROE21.7% · 20/25
- Net margin17.4% · 20/25
- Operating margin22.8% · 20/25
Health61
- Altman Z2.16 · 18/25
- Current ratio0.89 · 6/25
- Interest coverage12.7x · 25/25
- Net cash / debtD/A 24% · 12/25
Quality85
- Piotroski F5/9 · 15/25
- Beneish M-2.66 · 25/25
- FCF conversion104% · 25/25
- Margin stabilityσ 6.1% · 20/25
Moat68
- ROIC >12% years2/5 yrs · 6/25
- Median gross margin81.7% · 25/25
- FCF-positive years5/5 yrs · 25/25
- Worst-year net marginworst 0.3% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2026AcquisitionAstraZeneca held talks with Bristol Myers Squibb over a potential merger worth nearly $400 billion,…
- FY2025FinancialBest year on record$10.2B net income
- 2025AcquisitionAstraZeneca announced the acquisition of Belgian biotech company EsoBiotec for up to $1 billion to…
- FY2024FinancialRevenue crossed $50B$54.1B for the year
- FY2021FinancialProfitable every year on record5 consecutive profitable years in our data
- FY2021FinancialRevenue already above $10B$37.4B in first reported year
- FY2021FinancialPositive free cash flow every year since5-year streak
- 2020AcquisitionAstraZeneca made a preliminary approach to Gilead Sciences about a potential merger, worth almost…
- 2014AcquisitionThe company entered into a deal with Almirall to acquire its subsidiary Almirall Sofotec and its lung…
- 2012AcquisitionThen in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion
- 2011AcquisitionAstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business
- 2009AcquisitionAstraZeneca acquired Novexel Corp, an antibiotics discovery company formed in 2004 as a spin-off…
- 2007AcquisitionAstraZeneca's pipeline, and "patent cliff", was the subject of much speculation in April 2007 leading to…
- 2006AcquisitionSince the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate…
- 1913FoundedAstra AB was founded in 1913 in Södertälje, Sweden, by 400 doctors and apothecaries
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (81.3%)
- Strong cash conversion — FCF is 18.2% of revenue
- Interest covered 12.7× by operating earnings
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+8.6% YoY
- Profitable — makes more than it spends$10.2B FY2025
- Profit growing — earnings are higher than last year+45.9% YoY
- Generates cash — cash left after running and investing$10.7B FY2025
- Debt under control — could handle its obligations~2.6y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$247B market cap
- Not printing shares — share count not ballooning — you keep your slice+0.1% shares over ~5y
- Proven track record — years of profitability behind it5/5 profitable years
- Financially stable — balance sheet not near distressAltman Z 2.2 — grey
- Pays a dividend — returns cash to shareholdersyield 2.01%
- Valuation not extreme — price not wildly above earningsP/E 23.4
Peer comparisonAstraZeneca PLC vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| AZN this company | $246.9B | 23.4 | +8.6% | 17.4% | Solid |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: AZN vs LLY · AZN vs JNJ · AZN vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2021–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/AZN
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of AZN on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $159.20 · market cap $247B.